ThinkEquity Initiates Coverage on Gen-Probe (GPRO) with a Buy
More News related to GPRO
- Gen-Probe to Webcast Presentation at the 21st Annual Piper Jaffray Health Care Conference Today
- Neogen Acquires Gen-Probe's BioKits Food Safety Business
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
- Prodesse's ProParaflu+(TM) Assay Cleared for US Marketing by FDA
- Trading Review for Cerus Corp. Issued by Beacon Equity
More News related to New Coverage
- JANCO Partners Downgrades Energy Conversion Devices (ENER) to Sell
- Feltl & Co. Downgrades ArcSight (ARST) to Sell
- Credit Suisse Downgrades Comcast (CMCSA) to Neutral
- Citi Downgrades AK Steel (AKS) to Hold
- Citi Downgrades Netflix (NFLX) to Hold
ThinkEquity initiates coverage on Gen-Probe (Nasdaq: GPRO) with a Buy rating. Price target $55.
To see more analyst ratings on GRPO Click Here.
Gen-Probe Incorporated (Gen-Probe) is engaged in the development, manufacture and marketing of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood.
Related Categories
New CoverageStocks Mentioned
+0.99Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
